Stock Events

Novo Nordisk 

$138.31
5172
-$4.67-3.27% Wednesday 19:54

统计数据

当日最高
141.52
当日最低
136.01
52周最高
148.15
52周最低
74.66
成交量
7,179,327
平均成交量
3,745,017
市值
471.55B
市盈率
0
股息收益率
1.34%
股息
1.86

即将到来

股息

1.34%股息收益率
10年增长
16.17%
5年增长
24.83%
3年增长
36.17%
1年增长
80.72%

收益

2May已确认
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
2.93
5.85
8.78
预期每股收益
N/A
实际每股收益
5.68

人们还关注

此列表基于关注NVO的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

分析师评级

150.75$平均价格目标
最高估值为 $163。
来自过去6个月内的 4 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%

关于

Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Show more...
首席执行官
Lars Fruergaard Joergensen
员工
66015
国家
US
ISIN
US6701002056
WKN
000866931

上市公司